Printer Friendly

Dr. Reddya[euro](tm)s Laboratories unveils USFDA approved Gemcitabine for Injection.

M2 EQUITYBITES-July 28, 2011-Dr. Reddya[euro](tm)s Laboratories unveils USFDA approved Gemcitabine for Injection(C)2011 M2 COMMUNICATIONS

Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Wednesday the launch of Gemcitabine for Injection (200 mg/vial and 1g/vial) in the US market on 25 July 2011.

The company stated its United States Food & Drug Administration (USFDA) Gemcitabine for Injection is a bio equivalent generic version of Gemzar.

According to IMS Health, the Gemzar brand recorded US sales of approximately USD634m for the most recent 12 months ending 31 May 2011.

In addition, the company said its Gemcitabine for Injection 200mg/vial and 1 g/vial strengths are available in single-use vials.

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 28, 2011
Previous Article:Braskem SA acquires The Dow Chemical Company's USD323m Polypropylene business.
Next Article:-Spain's BBVA records decline in H1 profit.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters